FDA approves Retatrutide this year?
Recent trades
25- 0xbae5…45e3 SELL Yes $6.82 4h ago
- 0x69d7…c25c SELL No $42.18 4h ago
- 0x9089…17f2 BUY No $5.00 22h ago
- 0x97ea…3363 BUY No $80.77 Jul 23
- 0xcb58…ccd0 SELL Yes $0.75 Jul 23
- 0x1411…2410 BUY Yes $1.12 Jul 22
- 0x1411…2410 BUY Yes $1.12 Jul 22
- 0x1411…2410 BUY Yes $1.14 Jul 22
- 0x05c7…4421 SELL Yes $0.10 Jul 22
- 0xf20b…ae3c SELL No $19.23 Jul 22
- 0xf33e…0ab8 SELL Yes $0.23 Jul 22
- 0x7d33…c15f SELL No $31.14 Jul 22
- 0xba6c…618b SELL Yes $1.19 Jul 22
- 0xf33e…0ab8 SELL Yes $1.55 Jul 22
- 0xae7d…058f SELL Yes $2.16 Jul 22
- 0xc8a2…c9b6 SELL Yes $1.80 Jul 22
- 0xc3fc…484a SELL Yes $18.00 Jul 22
- 0x53d6…055a BUY No $465.00 Jul 22
- 0x4a74…7a5c SELL No $2.02 Jul 19
- 0x2b21…4fa9 SELL No $59.10 Jul 19
- 0x67b4…19ac BUY Yes $1.04 Jul 19
- 0xc8a2…c9b6 SELL Yes $1.51 Jul 18
- 0x63a8…0a89 SELL Yes $7.03 Jul 18
- 0xd43f…c66b BUY No $4.60 Jul 17
- 0x69d7…c25c BUY No $40.00 Jul 17
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Comments
Get yourself a chubby broad with a pretty face, import reta from China, wait 6 months and profit.
lmaoo no
Not easy to pass this trial.
Maybe. But this market has nothing to do with the trial really. Lilly hasn't even submitted the NDA or the BLA (not clear which path this will go). Either way the fastest time to approval is 6 months if they get priority review. Lilly announced positive Phase 3 results December 2025 with additional results anticipated in 2026. That tells me that aren't close to submitting yet. If they get the application in before June then maybe.